Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

NCT01876784 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

238

Enrollment

INDUSTRY

Sponsor class

Conditions

Differentiated Thyroid Cancer

Interventions

DRUG: Vandetanib (SAR390530)
DRUG: Placebo

Sponsor

Genzyme, a Sanofi Company